Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 114

1.

18F-fluorodeoxyglucose-positron emission tomography before, during and after treatment in mature T/NK lymphomas: a study from the GOELAMS group.

Cahu X, Bodet-Milin C, Brissot E, Maisonneuve H, Houot R, Morineau N, Solal-Celigny P, Godmer P, Gastinne T, Moreau P, Moreau A, Lamy T, Kraber-Bodere F, Le Gouill S.

Ann Oncol. 2011 Mar;22(3):705-11. doi: 10.1093/annonc/mdq415. Epub 2010 Aug 25.

PMID:
20739714
2.

Prognostic value of interim and posttherapy 18F-FDG PET/CT in patients with mature T-cell and natural killer cell lymphomas.

Li YJ, Li ZM, Xia XY, Huang HQ, Xia ZJ, Lin TY, Li S, Xia Y, Cai XY, Jiang WQ.

J Nucl Med. 2013 Apr;54(4):507-15. doi: 10.2967/jnumed.112.110262. Epub 2013 Feb 8.

3.

18F-fluorodeoxyglucose positron emission tomography in the staging and prognosis of T cell lymphoma.

Casulo C, Schöder H, Feeney J, Lim R, Maragulia J, Zelenetz AD, Horwitz S.

Leuk Lymphoma. 2013 Oct;54(10):2163-7. doi: 10.3109/10428194.2013.767901. Epub 2013 Mar 4.

4.

Assessment of the prognostic capacity of pretreatment, interim, and post-therapy (18)F-FDG PET/CT in extranodal natural killer/T-cell lymphoma, nasal type.

Jiang C, Zhang X, Jiang M, Zou L, Su M, Kosik RO, Tian R.

Ann Nucl Med. 2015 Jun;29(5):442-51. doi: 10.1007/s12149-015-0964-8. Epub 2015 Mar 24.

PMID:
25801633
5.

Fluorine-18 fluorodeoxyglucose positron emission tomography in mature T-cell and natural killer cell malignancies.

Khong PL, Pang CB, Liang R, Kwong YL, Au WY.

Ann Hematol. 2008 Aug;87(8):613-21. doi: 10.1007/s00277-008-0494-8. Epub 2008 May 29.

PMID:
18509641
6.

Utility of 18F-FDG PET/CT for staging NK/T-cell lymphomas.

Wu HB, Wang QS, Wang MF, Li HS, Zhou WL, Ye XH, Wang QY.

Nucl Med Commun. 2010 Mar;31(3):195-200. doi: 10.1097/MNM.0b013e32833310fa.

PMID:
20009963
7.

The value of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography for staging of primary extranodal head and neck lymphomas.

Schrepfer T, Haerle SK, Strobel K, Schaefer N, Hälg RA, Huber GF.

Laryngoscope. 2010 May;120(5):937-44. doi: 10.1002/lary.20843.

PMID:
20422687
8.

Midtreatment ¹⁸F-FDG PET/CT Scan for Early Response Assessment of SMILE Therapy in Natural Killer/T-Cell Lymphoma: A Prospective Study from a Single Center.

Khong PL, Huang B, Lee EY, Chan WK, Kwong YL.

J Nucl Med. 2014 Jun;55(6):911-6. doi: 10.2967/jnumed.113.131946. Epub 2014 May 12.

9.

18F-FDG PET for evaluation of the treatment response in patients with gastrointestinal tract lymphomas.

Kumar R, Xiu Y, Potenta S, Mavi A, Zhuang H, Yu JQ, Dhurairaj T, Dadparvar S, Alavi A.

J Nucl Med. 2004 Nov;45(11):1796-803.

10.

CT-based texture analysis potentially provides prognostic information complementary to interim fdg-pet for patients with hodgkin's and aggressive non-hodgkin's lymphomas.

Ganeshan B, Miles KA, Babikir S, Shortman R, Afaq A, Ardeshna KM, Groves AM, Kayani I.

Eur Radiol. 2017 Mar;27(3):1012-1020. doi: 10.1007/s00330-016-4470-8. Epub 2016 Jul 5.

11.

FDG-PET in T-cell and NK-cell neoplasms.

Kako S, Izutsu K, Ota Y, Minatani Y, Sugaya M, Momose T, Ohtomo K, Kanda Y, Chiba S, Motokura T, Kurokawa M.

Ann Oncol. 2007 Oct;18(10):1685-90. Epub 2007 Aug 22.

PMID:
17716987
12.

Evaluation of bone marrow involvement in extranodal NK/T cell lymphoma by FDG-PET/CT.

Zhou Z, Chen C, Li X, Li Z, Zhang X, Chang Y, Lu L, Cui Y, Ma Y, Zhang M.

Ann Hematol. 2015 Jun;94(6):963-7. doi: 10.1007/s00277-014-2289-4. Epub 2014 Dec 30.

PMID:
25547320
13.

Predictive value of (18)F-FDG hybrid PET/CT for the clinical outcome in patients with non-Hodgkin's lymphoma prior to and after autologous stem cell transplantation.

Qiao W, Zhao J, Wang C, Wang T, Xing Y.

Hematology. 2010 Feb;15(1):21-7. doi: 10.1179/102453310X12583347009739.

PMID:
20132658
14.

Combined modality treatment for PET-positive non-Hodgkin lymphoma: favorable outcomes of combined modality treatment for patients with non-Hodgkin lymphoma and positive interim or postchemotherapy FDG-PET.

Halasz LM, Jacene HA, Catalano PJ, Van den Abbeele AD, Lacasce A, Mauch PM, Ng AK.

Int J Radiat Oncol Biol Phys. 2012 Aug 1;83(5):e647-54. doi: 10.1016/j.ijrobp.2012.01.060. Epub 2012 May 18.

PMID:
22607911
15.

(18)F-FDG PET in Patients with Primary Systemic Anaplastic Large Cell Lymphoma: Differential Features According to Expression of Anaplastic Lymphoma Kinase.

Lee DY, Lee JJ, Kim JY, Park SH, Chae SY, Kim S, Yoon DH, Suh C, Huh J, Ryu JS.

Nucl Med Mol Imaging. 2013 Dec;47(4):249-56. doi: 10.1007/s13139-013-0224-6. Epub 2013 Aug 23.

16.

The value of [(18)F]fluorodeoxyglucose positron emission tomography/computed tomography in extranodal natural killer/T-cell lymphoma.

Karantanis D, Subramaniam RM, Peller PJ, Lowe VJ, Durski JM, Collins DA, Georgiou E, Ansell SM, Wiseman GA.

Clin Lymphoma Myeloma. 2008 Apr;8(2):94-9. doi: 10.3816/CLM.2008.n.010.

PMID:
18501102
17.

PET in T-Cell Lymphoma.

Zinzani PL.

Curr Hematol Malig Rep. 2011 Dec;6(4):241-4. doi: 10.1007/s11899-011-0098-6.

PMID:
21892600
18.

18F-FDG PET/CT for early response assessment in diffuse large B-cell lymphoma: poor predictive value of international harmonization project interpretation.

Cashen AF, Dehdashti F, Luo J, Homb A, Siegel BA, Bartlett NL.

J Nucl Med. 2011 Mar;52(3):386-92. doi: 10.2967/jnumed.110.082586. Epub 2011 Feb 14.

19.

The Deauville 5-Point Scale Improves the Prognostic Value of Interim FDG PET/CT in Extranodal Natural Killer/T-Cell Lymphoma.

Jiang C, Su M, Kosik RO, Zou L, Jiang M, Tian R.

Clin Nucl Med. 2015 Oct;40(10):767-73. doi: 10.1097/RLU.0000000000000892.

PMID:
26164182
20.

Diagnostic value of 18F-FDG PET/CT for cutaneous extranodal natural killer/T-cell lymphoma, nasal type.

Liu C, Zhang Y, Zhang Y, Wang M, Liu R, Liu X, Hu S.

Nucl Med Commun. 2016 May;37(5):446-52. doi: 10.1097/MNM.0000000000000463.

PMID:
26657218

Supplemental Content

Support Center